Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.2556
- Book/Share 19.1229
- PB 4.0006
- Debt/Equity 0.7209
- CurrentRatio 1.4103
- ROIC 0.2167
- MktCap 191842692000.0
- FreeCF/Share 6.7321
- PFCF 11.259
- PE 11.0915
- Debt/Assets 0.3027
- DivYield 0.0414
- ROE 0.3816
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
| Initiation | MRK | Bernstein | -- | Market Perform | -- | $115 | Oct. 17, 2024 |
News
2 Must-Own Dividends At Bargain Basement Prices
Published: April 28, 2025 by: Seeking Alpha
Sentiment: Positive
April's market volatility has created dividend bargains, allowing investors to pick high-quality blue-chip stocks with strong balance sheets and long-term return potential. Merck, trading at a low P/E of 9.3 and yielding 4.1%, carries a strong late-stage pipeline of 20 drugs. Schlumberger, with a P/E of 10.2 and a 3.3% yield, offers resilient growth prospects in offshore production and digital solutions.
Read More
Germany's Merck Set to Buy SpringWorks in $3.9 Billion Deal
Published: April 28, 2025 by: WSJ
Sentiment: Positive
The deal to acquire the U.S. biopharmaceutical company confirms an earlier report in The Wall Street Journal.
Read More
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Published: April 27, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a perioperative treatment regimen for patients with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Results at the first interim analysis of the trial showed KEYTRUDA significantly improved event-free survival (EFS) as pa.
Read More
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Published: April 26, 2025 by: The Motley Fool
Sentiment: Positive
Many investors are withdrawing their money from the stock market right now, but those focused on the long term know to hold on through market volatility. In fact, it's still a great time to invest in companies that have excellent underlying businesses and attractive long-term prospects.
Read More
Merck & Co., Inc. (MRK) Q1 2025 Earnings Call Transcript
Published: April 24, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (NYSE:MRK ) Q1 2025 Earnings Conference Call April 24, 2025 9:00 AM ET Corporate Participants Peter Dannenbaum - Senior Vice President, Investor Relations Rob Davis - Chairman and Chief Executive Officer Caroline Litchfield - Chief Financial Officer Dean Li - President of Merck Research Labs Conference Call Participants Geoff Meacham - Citi Tim Anderson - Bank of America Luisa Hector - Berenberg Vamil Divan - Guggenheim Securities Chris Schott - JPMorgan James Shin - Deutsche Bank Steve Scala - TD Cowen Alex Hammond - Wolfe Research Umer Raffat - Evercore Akash Tewari - Jefferies Mohit Bansal …
Read More
Merck (MRK) Reports Q1 Earnings: What Key Metrics Have to Say
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Merck (MRK) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Merck lowers profit outlook due to expected $200M tariff hit
Published: April 24, 2025 by: Proactive Investors
Sentiment: Negative
Merck & Co Inc (NYSE:MRK, ETR:6MK) has lowered its full-year earnings forecast due to an expected $200 million hit from global tariffs, notably levies between the US and China. The company now expects 2025 earnings per share (EPS) in the range of $8.82 to $8.97, down from its prior forecast of $8.88 to $9.03.
Read More
2 Blue-Chip Stocks Brushing Off Earnings Beats
Published: April 24, 2025 by: Schaeffers Research
Sentiment: Negative
Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance.
Read More
Cramer's Mad Dash: Merck
Published: April 24, 2025 by: CNBC Television
Sentiment: Neutral
Jim Cramer breaks down why he's keeping an eye on shares of Merck.
Read More
Merck absorbs $200 million in tariff costs into its earnings and full-year outlook
Published: April 24, 2025 by: Market Watch
Sentiment: Neutral
Shares of Merck & Co. were headed higher in early Thursday trading, after the drugmaker extended its long streak of quarterly earnings beats and held firm with its full-year outlook despite expected tariff costs.
Read More
Merck Stock Slumps Ahead Of Q1 Earnings: Can Bulls Find Relief In Buying Pressure?
Published: April 23, 2025 by: Benzinga
Sentiment: Negative
Merck & Co Inc MRK will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion.
Read More
The Setup: Chipotle, United Rentals, Merck and Pepsi
Published: April 23, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you The Setup on some key names reporting this week.
Read More
Merck Q1 Earnings Coming Up: Should You Buy the Stock Now?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
When Merck reports first-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Read More
Merck: Now A Single-Digit P/E With Double-Digit EPS Growth, Technical Support
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
Read More
Merck & Co.: Pipeline Resilience To Unlock Value
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. New product launches like WINREVAIR are exceeding expectations and offsetting pipeline risk.
Read More
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.
Read More
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142992&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
MRK DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 14, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?
Published: April 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Both ABBV and MRK are leading pharmaceutical companies with strong portfolios in oncology and immunology.
Read More
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
Published: April 14, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142959&wire=1 or contact Joseph E. Levi, Esq.
Read More
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRK
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142552&wire=1 or contact Joseph E. Levi, Esq.
Read More
Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
Published: April 11, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142540&wire=1 or contact Joseph E. Levi, Esq.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Levi & Korsinsky Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142316&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit - MRK
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=142310&wire=1 or contact Joseph E. Levi, Esq.
Read More
MRK FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
Published: April 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Mr. Robert M. Davis J.D.
- Employees 73000